Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery
NCT ID: NCT05240755
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
40 participants
INTERVENTIONAL
2022-07-01
2024-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
NCT04672252
Post-Operative Pain Control Following Shoulder Surgery
NCT04622839
Cannabis in Postoperative Pain Management
NCT06903624
A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones
NCT04387617
Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
NCT04988490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
Opioid standard of care: Tramadol 50 mg PO PRN #30, Hydrocodone/Acetaminophen 5/325 PO PRN #30
No interventions assigned to this group
Cannabidiol Oil 100 mg
CBD 100 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
Cannabidiol Oil
Subjects will self-administer CBD sublingually.
Cannabidiol Oil 200 mg
CBD 200 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
Cannabidiol Oil
Subjects will self-administer CBD sublingually.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabidiol Oil
Subjects will self-administer CBD sublingually.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Requiring shoulder arthroscopic surgery for soft tissue pathology
* Able to complete surveys and follow-up visits
Exclusion Criteria
* Shoulder dislocation, fracture, previous surgery, coexisting extremity pathology, pregnancy.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Foundation for Orthopaedic Research and Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael C. Doarn
Principal Investigator, Clinical Professor of Orthopaedic Surgery - USF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Florida Orthopaedic Institute
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USF003668
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.